There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biofrontera (BFRI – Research Report), Alpine Immune Sciences (ALPN – Research Report) and NewAmsterdam Pharma Company (NAMS – Research Report) with bullish sentiments.
Biofrontera (BFRI)
Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Biofrontera today and set a price target of $7.00. The company’s shares closed last Monday at $1.26, close to its 52-week low of $0.61.
According to TipRanks.com, Jackson is ranked 0 out of 5 stars with an average return of -20.3% and a 28.4% success rate. Jackson covers the Healthcare sector, focusing on stocks such as Belite Bio, Inc. ADR, Tenon Medical, Inc., and Exact Sciences.
Currently, the analyst consensus on Biofrontera is a Moderate Buy with an average price target of $16.00.
See the top stocks recommended by analysts >>
Alpine Immune Sciences (ALPN)
RBC Capital analyst Gregory Renza maintained a Buy rating on Alpine Immune Sciences yesterday and set a price target of $41.00. The company’s shares closed last Monday at $35.47, close to its 52-week high of $39.27.
According to TipRanks.com, Renza is a 5-star analyst with an average return of 15.0% and a 46.5% success rate. Renza covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals, Fusion Pharmaceuticals, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alpine Immune Sciences with a $37.80 average price target, a 3.7% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
NewAmsterdam Pharma Company (NAMS)
In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on NewAmsterdam Pharma Company, with a price target of $31.00. The company’s shares closed last Monday at $22.04.
According to TipRanks.com, Timashev is a 4-star analyst with an average return of 22.2% and a 48.8% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Edgewise Therapeutics, Axsome Therapeutics, and Legend Biotech.
NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $34.00, representing a 52.3% upside. In a report issued on March 13, Scotiabank also initiated coverage with a Buy rating on the stock with a $35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BFRI:
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKpomZ6Wubq%2F06xkraegYrWmrcutn5yZopp6sbXCpKpmmpmks7O7za2cq5ldl7OztYyao6mhnpp6qrnMrqWeZaOYtqa6wp6qZpmcpbtufY9sampvZmuGeg%3D%3D